Hormone Therapy Not Tied to T2DM, CV Risk in Postmenopausal Women

THURSDAY, Oct. 7, 2021 (HealthDay News) — Menopausal hormone therapy (MHT) is not associated with increased risks for cardiovascular disease or type 2 diabetes among middle-aged postmenopausal women, according to a Korean study published online Sept. 13 in Menopause.

Ji-Eun Kim, from the Seoul National University Graduate School in South Korea, and colleagues used the National Health Insurance Service database in Korea (2002 to 2016) to identify 58,060 postmenopausal women (8,013 MHT users and 50,047 nonusers). The authors evaluated the association between MHT and cardiovascular disease and type 2 diabetes.

The researchers found that MHT was not significantly associated with cardiovascular disease (hazard ratio, 1.085; 95 percent confidence interval, 0.899 to 1.310) or type 2 diabetes (hazard ratio, 1.104; 95 percent confidence interval, 0.998 to 1.221). Regimen type, cumulative duration, and years since menopause did not impact findings.

“Although protective effects of MHT against cardiovascular diseases or type 2 diabetes were not observed among postmenopausal women who had screened underlying diseases, our results may contribute to reducing the current concerns about the use of MHT for middle-aged postmenopausal women in Korea,” the authors write.

Abstract/Full Text (subscription or payment may be required)